M
Michael S. Ip
Researcher at University of Wisconsin-Madison
Publications - 87
Citations - 4521
Michael S. Ip is an academic researcher from University of Wisconsin-Madison. The author has contributed to research in topics: Visual acuity & Macular edema. The author has an hindex of 32, co-authored 67 publications receiving 4055 citations.
Papers
More filters
Journal ArticleDOI
A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Observation to Treat Vision Loss Associated With Macular Edema Secondary to Central Retinal Vein Occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 5
Michael S. Ip,Ingrid U. Scott,Paul C. VanVeldhuisen,Neal Oden,Barbara A Blodi,Marian R. Fisher,Lawrence J. Singerman,Michael J. Tolentino,Clement K. Chan,Victor H. Gonzalez +9 more
TL;DR: Intravitreal triamcinolone is superior to observation for treating vision loss associated with macular edema secondary to CRVO in patients who have characteristics similar to those in the SCORE-CRVO trial.
Journal ArticleDOI
Anatomical outcomes of surgery for idiopathic macular hole as determined by optical coherence tomography
Michael S. Ip,Brad J. Baker,Jay S. Duker,Elias Reichel,Caroline R. Baumal,Ronald E. Gangnon,Carmen A. Puliafito +6 more
TL;DR: The postoperative closure of idiopathic macular holes following vitreous surgery was related to the preoperative macular hole diameter determined by OCT, with lesions smaller than 400 microm demonstrating higher success rates.
Journal ArticleDOI
Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema.
Roy W. Beck,Allison R. Edwards,Lloyd Paul Aiello,Neil M. Bressler,Frederick L. Ferris,Adam R. Glassman,Elizabeth Hartnett,Michael S. Ip,Judy E. Kim,Craig Kollman +9 more
TL;DR: The 3-year outcomes of patients who participated in a randomized trial evaluating 1-mg and 4-mg doses of preservative-free intravitreal triamcinolone compared with focal/grid photocoagulation for treatment of diabetic macular edema were reported in this article.
Journal ArticleDOI
Long-term effects of ranibizumab on diabetic retinopathy severity and progression.
TL;DR: Intravitreal ranibizumab reduced the risk of DR progression in eyes with diabetic macular edema, and many ranibzumab-treated eyes experienced improvement in DR severity.
Journal ArticleDOI
Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion.
Michael S. Ip,Justin L. Gottlieb,Alon Kahana,Ingrid U. Scott,Michael M. Altaweel,Barbara A Blodi,Ronald E. Gangnon,Carmen A. Puliafito +7 more
TL;DR: Intravitreal injection of triamcinolone appears to be a possibly effective treatment in some patients with macular edema associated with central retinal vein occlusion and patients with nonischemic CRVO may respond more favorably than patients with ischemic CRVO.